Our Vision
Context is dedicated to developing the next generation of therapies to treat solid tumors.
Lead Program
CTIM-76 is a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors currently in preclinical development. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, lung, and testicular, and absent from or expressed at low levels in healthy adult tissues.